“The results being presented at SID provide further scientific rationale for targeting OSMRβ and dual pathway inhibition of IL-31 and OSM via KPL-716 for the potential treatment of chronic pruritic diseases,” said Dr.
Presentations include:
KPL-716, Anti-OSMRβ Antibody, Reduced Pruritus in Atopic Dermatitis
- Oral Presentation: Concurrent Mini-Symposium #4 on
Thursday, May 9 th, 2019 from1:30 p.m. to 4:00 p.m. Central Time in International Ballroom South - Poster Presentation: Poster Session III (#560) on
Saturday, May 11 th, 2019 from12:45 p.m. to 2:45 p.m. Central Time in Stevens Salons B/C/D - Lead Author: Zamaneh Mikhak,
Kiniksa Pharmaceuticals Corp. ,Lexington, Massachusetts , USA
OSM Induction of Monocyte Chemoattractant Protein 1 (MCP-1) in Human Epidermal Keratinocytes is Inhibited by Anti-OSMRβ Monoclonal Antibody KPL-716
- Poster Presentation: Poster Session I (#637) on
Thursday, May 9 th, 2019 from10:45 a.m. to 12:45 p.m. Central Time in Stevens Salons B/C/D - E-Poster Presentation: E-Poster Discussions II on
Friday, May 10 th, 2019 from10:45 a.m. to 11:45 a.m. Central Time in Continental Ballroom C - Lead Author:
Carl D. Richards ,McMaster Immunology Research Centre ,McMaster University ,Hamilton, Ontario, Canada
The OSMRβ Axis Identified in Prurigo Nodularis
- Poster Presentation: Poster Session I (#202) on
Thursday, May 9 th, 2019 from10:45 a.m. to 12:45 p.m. Central Time in Stevens Salons B/C/D - Lead Author: Zamaneh Mikhak,
Kiniksa Pharmaceuticals Corp. ,Lexington, Massachusetts , USA
KPL-716, an OSMRβ Monoclonal Antibody, Reduces IL-31-Induced Scratching Behavior in Cynomolgus Monkeys: Establishment and Optimization of Pharmacokinetic/Pharmacodynamic Model
- Poster Presentation: Poster Session II (#1002) on
Friday, May 10 th, 2019 from11:15 a.m. to 1:15 p.m. Central Time in Stevens Salons B/C/D - Lead Author:
Rohan Gandhi ,Kiniksa Pharmaceuticals Corp. ,Lexington, Massachusetts , USA
Kiniksa intends to make the abstracts available through the Investors and Media section of its website (www.kiniksa.com) upon their publication in the
About KPL-716
KPL-716 is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of IL-31 and OSM, two key cytokines implicated in pruritus, inflammation and fibrosis. Kiniksa believes KPL-716 to be the only monoclonal antibody in development that targets both pathways simultaneously.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.
Every Second Counts!™
Kiniksa Investor and Media Contact
(781) 430-8289
mragosa@kiniksa.com
Source: Kiniksa Pharmaceuticals, Ltd.